All In Biotech

Drug Trial Radar · NCT00887627

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

A Phase 1, Open-Label Study to Assess the Effects of Renal Impairment on the Pharmacokinetics of Intravenous Conivaptan

Last checked: Nov 19, 2026Latest source record: May 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Apr 2009

Primary completion

Jul 2010

Study completion Jul 2010

Sponsor

Lead sponsor
Cumberland PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Apr 24, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to compare a conivaptan PK in subjects with mild or moderate kidney function impairment to subjects with normal kidney function after a 48-hour continuous infusion of conivaptan.

Conditions

  • Kidney Diseases
  • Hyponatremia

Interventions

  • conivaptan hydrochlorideDrug

    intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Measure PK and protein binding of conivaptanTime frame: 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.